After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the Diagnostics Accelerator (DxA) to fund innovations as a venture philanthropy fund. The AD field had seen rapid advances in therapeutics, and as such, large corporations were hesitant to take venture funding which meant potentially losing control and having other opinions on the Board. Instead, these companies were turning to other non-dilutive sources of funding. The DxA, and GV, sat at a crossroads and needed to determine where to go next to fulfill their mission.

Supplements the (A) case, 824020. Following on the negotiations detailed in the Miracle Therapeutics (A) case, Beth Sharp and Jennifer Brilliant from Miracle Therapeutics face new challenges with their company's funding and intellectual property (IP) after several missteps. The company and its young CEO are at a crossroads and must solve the challenges faced by many early-stage life science companies. The case follows how they navigate these issues to set Miracle on the right course.

In 2019, Moderna faced long odds of survival having failed to develop a successful clinical program out of the vast platform technology they had built around mRNA. Nearly overnight, the company skyrocketed to success with a vaccine for COVID-19, leading to an extremely fast ramp-up in manufacturing relying heavily on contract manufacturing organizations (CMOs) to produce hundreds of millions of doses of a single vaccine. However, on the heels of Moderna's COVID success, the company had more than 40 clinical programs in the pipeline, and as they moved towards personalized vaccines, had to determine what the future of manufacturing would look like for a company that needed to produce massive amounts of certain products and a handful of doses of others.

Born out of a desire to bring technological advances in enterprise software into the healthcare vertical, Peter Gassner and Matt Wallach founded Veeva to bring life sciences companies into the digital age for data management in both the commercial and R&D sectors. Over the course of years of growth, the company expanded to take a commanding share of the market and become the nearly-uniform "operating system" for life sciences companies. Veeva also became the first Public Benefits Corporation (PBC) in the U.S. to enshrine their objectives for the industry within their business model and as one of five stakeholders, along with shareholders, as a for-profit company. Veeva is now at a crossroads and must decide where to go to ensure compliance with their objectives as a PBC, continue their growth and expansion, and ensure they maintain market share. What should the company do?

After pivoting from a focus on hardware to a focus on scientific data, TetraScience, led by veteran SaaS executive, Patrick Grady and Founder Spin Wang, has embarked on a journey from nearly cash-out to a player in the scientific data management space. This case focuses on challenges within the scientific data space today, including TetraScience's approach to building a two-sided network, and how the company plans to utilize the pivot as a way to address one or both sides of that network and build upon their desired new business model. Where should TetraScience look to expand their total addressable market (TAM) and capture market share in an industry where companies know they have a need to solve their data issues, but have a ton of inertia holding the industry within the status quo?

After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening years, but questions still remained concerning the strategic about-face. Thermo Fisher, often referred to as the 800lb gorilla in the room, was already nearly a one-stop-shop for biotech and pharma companies. Now, with the acquisition complete, Thermo Fisher and its customers faced a bit of a reckoning, with many potential paths forward. What would the right path for Thermo Fisher and its customers be?

Catalent's newly appointed CEO, Alessandro Maselli, experienced the highs of the pharmaceutical contract development manufacturing (CDMO) space during COVID-19 while helping Moderna and others bring vaccines to market quickly and safely. After rushing to add capacity to help deal with the pandemic, demand for CDMO services dried up post-pandemic, leaving Maselli and Catalent to pick up the pieces. Once considered as an acquisition target by other industry giants, Catalent dealt with several struggles, including a departing CFO, several issues with plants, and declining demand. How can Maselli turn the ship around and drive Catalent to even higher heights moving forward?

After selling the PerkinElmer name and several ancillary business units, Prahlad Singh (CEO) and his team at the newly christened Revvity faced a challenge on how best to capitalize on the opportunities ahead for the business and emerge as winners within the Life Sciences and Diagnostics industries. Would the focus on Life Sciences and Diagnostics allow Singh to capture the value in the market that eluded him when PerkinElmer was saddled with other non-core businesses, or would challenges persist by trading at lower multiples than their peers? Singh and the company had a clean slate, and needed to craft a corporate strategy that focused on core strengths and showcased the unpolished gems that Revvity had acquired and polished into a global stable of respected brands.

Jake Becraft, a PhD student at MIT disillusioned in pursuit of his dreams of becoming an academic, serendipitously finds himself discussing the potential commercial applications of his work with Tasuku Kitada, his former postdoctoral research mentor. The two decide to alter the course of both of their lives, join forces, and begin down an entrepreneurial road to found Strand Therapeutics. The journey features the genesis of Becraft's ideas, the pursuit of those ideas, the path to entrepreneurship and the associated challenges, including many bumps, twists and turns along the way.

Beth Sharp and Jennifer Brilliant founded Miracle Therapeutics based on intellectual property developed by Brilliant and her post-doctoral student, John Supreme, in Brilliant's lab at Elite University (EU). Miracle will have to obtain a license from EU to the Brilliant patent rights and other technology, and the founders want this license to be exclusive. With venture funding waiting in the wings, Sharp and Brilliant set up a meeting with EU's Technology License Office (TLO) to discuss the terms of the license. The TLO's licensing manager, Susie Deal-maker has provided them with a licensing term sheet template for review prior to negotiating the key terms. The case explores the components of a technology/IP license and the process of negotiating a deal with a University.

Coming out of the COVID-19 pandemic, Moderna was riding the successes of developing a vaccine in record time and helping stem the tide of the crisis. However, the company had grown at an incredible rate, more than doubled its number of employees, and had to put on hold desired projects to push the company to continue to innovate and push the boundaries as a digital-first biotech company. The retirement of CTO and Moderna's digital architect, Marcello Damiano, prompted the company to reevaluate how best to proceed. The choice for who would replace him loomed large over many aspects of the company's strategy moving forward, and could potentially reshape its future.